Case report: Exploring teduglutide as a therapeutic option for refractory microscopic colitis: insights and implications
Case report: Exploring teduglutide as a therapeutic option for refractory microscopic colitis: insights and implications is a paper indexed in PICO Portal from OpenAlex.
How many citations does Case report: Exploring teduglutide as a therapeutic option for refractory microscopic colitis: insights and implications have?
Case report: Exploring teduglutide as a therapeutic option for refractory microscopic colitis: insights and implications has 5 citations in the OpenAlex counts PICO Portal stores.
When was Case report: Exploring teduglutide as a therapeutic option for refractory microscopic colitis: insights and implications published?
Case report: Exploring teduglutide as a therapeutic option for refractory microscopic colitis: insights and implications has 2023 year in the PICO Portal index.
What is the open-access status of Case report: Exploring teduglutide as a therapeutic option for refractory microscopic colitis: insights and implications?
Case report: Exploring teduglutide as a therapeutic option for refractory microscopic colitis: insights and implications has gold oa status in the PICO Portal index.
What is the DOI of Case report: Exploring teduglutide as a therapeutic option for refractory microscopic colitis: insights and implications?
The DOI for Case report: Exploring teduglutide as a therapeutic option for refractory microscopic colitis: insights and implications is on the source record.
What is the PMID of Case report: Exploring teduglutide as a therapeutic option for refractory microscopic colitis: insights and implications?
The PMID for Case report: Exploring teduglutide as a therapeutic option for refractory microscopic colitis: insights and implications is on the source record.
What is the OpenAlex record for Case report: Exploring teduglutide as a therapeutic option for refractory microscopic colitis: insights and implications?
The OpenAlex for Case report: Exploring teduglutide as a therapeutic option for refractory microscopic colitis: insights and implications is on the source record.